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Abstract
Biomonitoring, the determination of chemical substances in human body fluids or tissues, is more
and more frequently applied. At the same time detection limits are decreasing steadily. As a
consequence, many data with potential relevance for public health are generated although they
need not necessarily allow interpretation in term of health relevance. The European Centre of
Ecotoxicology and Toxicology of Chemicals (ECETOC) formed a dedicated task force to build a
framework for the interpretation of biomonitoring data. The framework that was developed
evaluates biomonitoring data based on their analytical integrity, their ability to describe dose
(toxicokinetics), their ability to relate to effects, and an overall evaluation and weight of evidence
analysis. This framework was subsequently evaluated with a number of case studies and was shown
to provide a rational basis to advance discussions on human biomonitoring allowing better use and
application of this type of data in human health risk assessment.
Introduction
Biomonitoring, the measurement of the concentrations of
chemical substances in human body fluids and tissues,
has been routinely applied in industry and parts of the
public health arena for more than 50 years [1]. The con-
tinuously increasing availability of analytical methodolo-
gies in combination with a constant decrease in detection
limits has rendered biomonitoring both more accessible
and more sensitive. As a consequence, biomonitoring is
more and more frequently applied in various health set-
tings. This leads primarily to an increase in the available
knowledge on the extent of human exposure to chemical
substances. In addition, it may create a number of oppor-
tunities for improving human health risk assessment
because it triggers new research investigating the links
between low-level exposures, adverse health effects, and
potentially vulnerable population groups. On the other
hand, the use of biomonitoring data creates a number of
challenges, not least because the nature of biomonitoring
findings is often heterogeneous. As a consequence, there
is an emerging need to ensure that biomonitoring data are
interpreted within the boundary in which they can be reli-
ably applied. This is of particular interest in view of the
increased attention for personalised exposure informa-
tion from the general public when adverse health effects
are merely suspected from environmental exposure to
chemicals [2]. It also stresses the importance of scientifi-
cally sound and reliable interpretation of biomonitoring
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data. In this respect, it should be emphasised that much
apposite learning can be gleaned from examining the
accumulated experiences arising from the past use of bio-
monitoring in occupational and public health settings.
ECETOC is a non-profit, non-advocacy, scientific organi-
sation funded by over 40 of the major chemical producing
and using companies in Europe. It was founded in 1978
with the aim of improving the understanding of the
human and environmental risks arising from the manu-
facture and use of chemicals. ECETOC has published over
300 peer reviewed reports and publications, and holds the
status of a non-governmental organisation (NGO) status
at the WHO and at several other world and European bod-
ies.
Given this emerging trend for increased availability of bio-
monitoring data, ECETOC constituted a Task Force, com-
prising members from industry, academia and non-
governmental organisations, to develop a framework in
which biomonitoring data can be consistently evaluated
and which can be used to foster a consistent basis for the
application of biomonitoring data for risk assessment
purposes.
The Task Force was made up of the following persons:
• Dr. P.J. Boogaard (chairman), Shell International, NL;
￿ Prof. Dr. P.B. Farmer, Univ. Leicester, UK;
￿ Dr. M. Holt, ECETOC, B;
￿ Prof. Dr. L.E. Knudsen, Univ. Copenhagen, DK;
￿ Dr. L. Onyon, WHO, CH;
￿ Dr. S.H. Robison, Procter and Gamble, USA;
￿ Prof. Dr. G. Schoeters, VITO, B;
￿ Dr. G.D. Stropp, Bayer HealthCare, D;
￿ Dr. M.F. Wilks, Syngenta Crop Protection, CH;
￿ Dr. W. Will, BASF, D.
This article will give an overview of the framework as laid
out by this Task Force and identify a number of areas that
require further development and discussion to ensure the
reliable and responsible use of human biomonitoring
data.
The need for human biomonitoring data in risk 
assessment
Biomonitoring is a general term that includes various lev-
els of determining exposure and effects and comprises the
following subcategories:
1. Biological monitoring or biomarkers of exposure (also:
internal dose or body burden);
2. Biochemical effect monitoring or biomarkers of effec-
tive dose (also: tissue dose);
3. a. Biological effect monitoring or biomarkers of effect
b. Clinical parameters or biomarkers of disease.
In addition, both phenotype and genotype may be
referred to as biomarkers of susceptibility. Biomonitoring
is part of the suite of monitoring techniques in the expo-
sure-disease continuum as illustrated in Figure 1. In devel-
oping the framework for the interpretation of
biomonitoring data, the Task Force focussed on biological
monitoring and biochemical effect monitoring as these
both provide chemical-specific internal exposure data
whereas the data in the third category (biomarkers of
effect and of disease) can not directly be linked to chemi-
cal exposure. This does not imply that that the Task Force
considered these data not useful. On the contrary, like the
other biomonitoring data they form part of the large body
of human experience data, which various authorities have
recognised, needs to be incorporated into the risk assess-
ment process to improve the utility and robustness of the
assessments [3-5].
Human data can present in many forms, ranging from the
findings of epidemiological studies to the results of work-
place or public health surveillance programmes [6].
Amongst various attributes, human experience data in its
various forms enables;
1) New health effects to be identified e.g. through epide-
miology or case studies;
2) Calibration of the results from animal findings against
the human experience;
3) Human effect levels to be defined with more certainty.
For risk assessment it is crucial that a reliable causal rela-
tionship can be established between a specific human
health effect and a specific (chemical) exposure. Human
biomonitoring, especially at the public health level, can
play a crucial role in establishing such a causal relation-
ship. Therefore, at the European level, the incorporation
of human data into the risk assessment process was specif-Environmental Health 2008, 7(Suppl 1):S12 http://www.ehjournal.net/content/7/S1/S12
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ically encouraged [4]. Nevertheless, this focus seems to
fade in the new chemicals legislation (REACH) that states
that human test data are 'generally not acceptable'. How-
ever, this statement may be a mere reflection of some EU
member states' view not to encourage human volunteer
testing. If not, it would seriously undermine the very aims
of REACH since it would not only deny the intrinsic value
that human data itself brings to the risk assessment proc-
ess but also fail to recognise that many health effects of
concern cannot be identified from animal studies e.g. res-
piratory sensitization, myeloid leukaemia, headaches, etc.
The use of human data is further reinforced by animal
welfare considerations since the need to initiate animal
testing is questionable if good quality data from human
experiences are available. In addition, the use of human
data reduces uncertainty since assessment factors for inter-
species extrapolation are superfluous when human data
are used.
Guidelines for the interpretation of human biomonitoring 
data
The Task Force accepted the risk management paradigm as
formulated by the European Union (Figure 2), which
requires a dose-response relationship together with expo-
sure data to characterize the health risk of a specific chem-
ical hazard to subsequently decide whether the risk is such
that management is required. In the standard European
Union risk assessment process, the risks for industrial
operators, for consumers and for 'man through the envi-
ronment' is assessed. The last category relates to health
risks of the general public potentially caused by exposure
from chemical substances in the environment. Human
biomonitoring is ideally suited to assess this level of expo-
sure as, by its very nature, it integrates all routes of expo-
sure (oral, dermal and by inhalation) and provides
currently the most reliable and relevant integrated expo-
sure metric.
The Task Force identified four specific elements which,
dependent on the degree to which each is supported,
allow any set of biomonitoring data to be evaluated with
respect to the extent to which it can be applied to different
stages of the risk assessment process. The four elements
are:
• Analytical integrity
The analytical integrity includes (1) consideration of
internal quality control factors, such as the availability of
standard operating procedures for the pre-analytical
phase (sample collection, sample storage), the analytical
phase (actual analytical procedures, quality controls
including external quality control when available), as well
as the post-analytical phase (statistical analyses of the
data, reporting of the results), (2) standardisation of con-
ditions for sample collection and storage, (3) determina-
tion of recoveries, reproducibility and accuracy (which
Monitoring techniques as part of the exposure-disease continuum Figure 1
Monitoring techniques as part of the exposure-disease continuum.
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should all be in an acceptable range) for analytical meth-
ods used, (4) availability of reference standards, and (5)
the use of control samples and 'blank' samples, which
should ensure that there is no contamination or artifac-
tual production of the analyte caused by the sample isola-
tion or analysis. A typical example of this can be seen with
oxidative DNA damage: for the same biological sample
different methodologies resulted in measured concentra-
tions of 8-oxo-7,8-dihydroguanine (the most ubiquitous
oxidation product of guanine) that differed more than 2
orders of magnitude. [7]. The reasons for this discrepancy
was found to originate from adventitious oxidation of
guanine during the isolation of the DNA and subsequent
derivatisation.
• Ability to describe dose (toxicokinetics)
For risk assessment of a specific chemical substance
knowledge of the dose, defined as the exposure to this
substance as a function of time, is essential. Biological
monitoring and biochemical effect monitoring provide a
snapshot of those substances or their metabolites present
in the body independent of the route of exposure and
thus, make it possible to draw conclusions on the inte-
grated dose. For differentiating between exposures, the
monitoring method must be selective and measure exclu-
sively the object of the biomonitoring programme. This
selectivity depends not only on analytical specificity, but
also, especially in situations in which the biomarker is not
the parent chemical, on other sources of the metabolite
from other chemicals. Not only is the choice of a suitable
biomarker essential, but its disposition kinetics are also
important with respect to the possible biological variabil-
ity relative to external chemical exposure. Furthermore, to
be able to relate biomonitoring data back to exposure, a
detailed knowledge of human metabolism and toxicoki-
netics, including their biological variability [8], is desira-
ble, if not, essential.
• Ability to relate data to effects
Important aspects for the ability to relate biomarker con-
centrations to effects are (1) the knowledge of background
levels in the general population, (2) the relation between
external and internal exposure, (3) the relation between
biomarker concentration and the total dose, (4) the esti-
mation of the inter- and intra-individual variability, and
(5) the evaluation of confounding factors (including sys-
tematic errors) that can affect the biomarker. The Task
Force recognised that there is a considerable lack of
knowledge of low-dose response relationships which
makes it difficult to establish causal relationships between
biomonitoring (or other exposure) data and observed
effects. Criteria classically used to establish such a causal-
ity may be helpful here, such as those proposed by Brad-
ford-Hill [9] and further developed by Vineis and Porta
[10], whilst the overall validity needs to be considered by
evaluating analytical integrity, the relevance, specificity
and sensitivity. This may, for example, be done by apply-
ing the framework developed by IPCS, which evaluates
the collective information from diverse datasets in a struc-
tured manner to provide objective assessments of the
state-of-the-science of determining causality between
exposure to a chemical and selected health outcomes [11].
Moreover, any biomarker study related to health effects
should be hypothesis driven [12]. The hypothesis of a
causal relationship between biomarkers of exposure and
observed effects needs to be set in advance, prior to the
initiation of the study. The hypothesis under study should
be based on an understanding of the mode of action of a
chemical wherever possible, on animal data, or on com-
parative epidemiological studies. A good example of this
is given by the studies on aflatoxin B1 biomarkers, where
the relationship between aflatoxin ingestion and hepato-
cellular carcinoma was evident from epidemiological
studies. In a series of elegant studies, it was shown that
there was no statistically significant association between
the risk of liver cancer and dietary aflatoxin intake (i.e.
external exposure) but a highly significant correlation
between hepatocellular carcinomas and the internal expo-
sure to aflatoxin, as measured by the determination of uri-
nary aflatoxin B1 metabolites, especially its major DNA
adduct (aflatoxin-N7-guanine) [13-16]. Moreover, the
effectiveness of intervention policies could be followed
through biomonitoring. Dietary chlorophyllin reduced
aflatoxin B1 DNA adducts in rats and prevented against
hepatocarcinogenesis and a significant reduction in uri-
nary aflatoxin-N7-guanine was also measured in human
populations treated with this chemoprotective agent [17].
Similarly, dramatic reductions in blood lead concentra-
Process for risk characterisation and management (adapted  from [4]) Figure 2
Process for risk characterisation and management (adapted 
from [4]).
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tions in children were observed following the introduc-
tion of policies to ban lead in paints and automotive fuels
[18-20].
• Overall evaluation and weight of evidence
Evaluation of causal criteria that link an exposure to a spe-
cific effect can be highly complex. It often involves inte-
gration of data from many studies that differ in terms of
experimental conditions and the parameters examined.
This is termed the 'weight of evidence' approach and used
in different areas of evaluation (see for instance [21]). The
weight of evidence approach is the evaluation of all avail-
able data on a specific compound or hypothesis and has
to be done as a case-by-case evaluation usually requiring
expert judgment.
The approach followed by the Task Force to categorise
data builds off the general guidance contained in earlier
publications [22] and is shown in Figure 3. Analysis of the
extent to which any set of biomonitoring data are sup-
ported by the 'required knowledge', enables to determine
the main risk assessment functions that these data can be
reliably be applied to. Specifically, these functions are to:
￿ Establish exposure patterns and trends;
￿ Characterise the nature of exposures;
￿ Investigate linkages between exposure and adverse
health effects; and
￿ Facilitate risk management, including standard setting.
Recommendations and conclusions
The proposed approach to interpreting biomonitoring
results is intended both to offer a considered view of the
available science aànd to serve as a catalyst for stimulating
discussion on some of the broader issues presented by the
application of biomonitoring technologies today [23].
The utility of the approach was tested in a series of illus-
trative case studies, which made it possible to identify
where different types of biomonitoring data can be relia-
bly used and to indicate their relative importance. It also
allowed identifying where and how they can be incorpo-
rated into a framework that provides the basis for their
consistent interpretation whilst accounting for the current
level of understanding of the supporting science.
In developing the framework, a number of areas were
identified as requiring further work. These included (1)
further validation to better establish the boundaries
within which biomonitoring can be reliably applied –
specifically, further work should be undertaken to more
clearly define how biomarkers of effect and susceptibility
(see Fig. 1) could reliably be incorporated, (2) develop-
ment of a more extensive library of case studies that would
serve as a training tool to help risk assessors etc. under-
stand how different forms of biomonitoring data should
be evaluated and applied, (3) development of guidance
on how study findings should be communicated to differ-
ent interest groups; this guidance would need to cover the
communication of results to individuals and groups, as
well as including the wider communication of findings to
external audiences, and (4) clarification on the rules and
considerations that govern the ethics of how biomonitor-
ing surveys and programmes are initiated, managed and
maintained; rules which could provide a basis for such
guidance exist, but the extent to which biomonitoring sur-
veys, particularly those undertaken in the public health
setting, address these issues is currently inconsistent and
the development of clear and concise ethically-based
guidance in this area would help minimise this. In addi-
tion, clear and succinct guidance on the practical aspects
of how and in what context such studies might be under-
taken in practice would be helpful. A number of these
areas are currently being addressed by ESBIO (the Expert
team to Support BIOmonitoring in Europe, is an expert
network is funded by the European Commission (Direc-
torate-General Research) under the 6th Framework Pro-
gramme for Research and Technological Development in
close cooperation with Directorate-General Environment
http://www.eu-humanbiomonitoring.org.
In conclusion, a framework was developed that provides
a rational basis on which to further the discussion on
human biomonitoring and will hopefully lead to the bet-
ter use and application of this type of data in human
health risk assessment. The full report can be downloaded
from the ECETOC website at http://www.ecetoc.org.
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The Proposed Framework for the Evaluation of Biomonitor- ing Data Figure 3
The Proposed Framework for the Evaluation of Biomonitor-
ing Data.
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